Patients Exploring the role of pharmacy and self-care in the fight ag... Globally, the incidence of fatty liver disease is increasing at a concerning rate, yet, the solution could be simple.
R&D How clinical research is zeroing in on fatty liver disease Americans’ livers are becoming increasingly unhealthy.
News 89bio shows its NASH hand, boosting FGF21 concept Positive phase 2b results on liver fibrosis follow similar data with a rival drug from Akero.
News Akero rockets as NASH drug hits targets in phase 2b trial A drug developed by US biotech Akero Therapeutics has hit the mark in a phase 2b trial in non-alcoholic steatohepatitis (NASH) – catapulting it to the forefront of efforts to find effective
Patients Fatty liver disease: With little early detection, more chall... For most of my adult life, I had been the typical American fat guy, gaining a pound or two a year and thinking little of it.
News Regeneron swoops on genetic testing firm 23andMe DNA testing company 23andMe looks destined to be taken over by a pharma company, as Regeneron agrees a $256 million acquisition deal.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
